Katchanov Juri, Kreuels Benno, Maurer Florian P, Wöstmann Kai, Jochum Johannes, König Christina, Seoudy Kariem, Rohde Holger, Lohse Ansgar W, Wichmann Dominic, Baehr Michael, Rothe Camilla, Kluge Stefan
Department of Intensive Care Medicine, University Medical Center Hamburg-Eppendorf, Martinistr. 52, 20246, Hamburg, Germany.
Division of Infectious Diseases and Tropical Medicine, First Medical Department, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.
BMC Infect Dis. 2017 Feb 8;17(1):131. doi: 10.1186/s12879-017-2229-8.
Inappropriate use of broad-spectrum antimicrobials affects adversely both the individual patient and the general public. The aim of the study was to identify patients at risk for excessively prolonged carbapenem treatment in the ICU as a target for antimicrobial stewardship interventions.
Case-control study in a network of 11 ICUs of a university hospital. Patients with uninterrupted meropenem therapy (MT) > 4 weeks were compared to controls. Controls were defined as patients who stayed on the ICU > 4 weeks and received meropenem for ≤ 2 weeks. Associations between case-control status and potential risk factors were determined in a multivariate logistic regression model.
Between 1 of January 2013 and 31 of December 2015, we identified 36 patients with uninterrupted MT > 4 weeks. Patients with prolonged MT were more likely to be surgical patients (72.2% of cases vs. 31.5% of controls; p ≤ 0.001) with peritonitis being the most common infection (n = 16, 44.4%). In the multivariate logistic regression model colonization with multidrug-resistant (MDR) Gram-negative bacteria (OR 7.52; 95% CI 1.88-30.14, p = 0.004) and the type of infection (peritonitis vs. pneumonia: OR 16.96, 95% CI 2.95-97.49) were associated with prolonged MT.
Surgical patients with peritonitis and patients with known colonization with MDR Gram-negative bacteria are at risk for excessively prolonged carbapenem therapy and represent an important target population for antimicrobial stewardship interventions.
广谱抗菌药物的不当使用对个体患者和公众均有不利影响。本研究的目的是确定重症监护病房(ICU)中碳青霉烯类药物治疗时间过长的高危患者,作为抗菌药物管理干预的目标。
在一所大学医院的11个ICU组成的网络中进行病例对照研究。将美罗培南治疗(MT)持续时间>4周的患者与对照组进行比较。对照组定义为在ICU住院时间>4周且接受美罗培南治疗≤2周的患者。在多变量逻辑回归模型中确定病例对照状态与潜在风险因素之间的关联。
在2013年1月1日至2015年12月31日期间,我们确定了36例MT持续时间>4周的患者。MT延长的患者更有可能是外科患者(病例组72.2% vs. 对照组31.5%;p≤0.001),腹膜炎是最常见的感染类型(n = 16,44.4%)。在多变量逻辑回归模型中,多重耐药(MDR)革兰氏阴性菌定植(比值比7.52;95%置信区间1.88 - 30.14,p = 0.004)和感染类型(腹膜炎与肺炎:比值比16.96,95%置信区间2.95 - 97.49)与MT延长有关。
患有腹膜炎的外科患者和已知有MDR革兰氏阴性菌定植的患者有碳青霉烯类药物治疗时间过长的风险,是抗菌药物管理干预的重要目标人群。